Characteristics of metastatic lung cancer patients on osimertinib therapy in Bangladesh

M. Arifur Rahman; Taohida Yasmin; Sadia Sharmin; Arman Reza Chowdhury; M. Mohsin Howlader; S. M. Rokonuzzaman; Meher Zabin; Kamrun Nahar Tania; Arunangshu Das

doi:10.18203/2320-6012.ijrms20250962

Authors

M. Arifur Rahman Department of Oncology and Radiotherapy, Bangladesh Specialized Hospitals Limited, Dhaka, Bangladesh
Taohida Yasmin Department of Radiation Oncology, Evercare Hospital, Dhaka, Bangladesh
Sadia Sharmin Department of Radiation Oncology, Evercare Hospital, Dhaka, Bangladesh
Arman Reza Chowdhury Department of Radiation Oncology, Evercare Hospital, Dhaka, Bangladesh
M. Mohsin Howlader Department of Radiotherapy, Sher-E-Bangla Medical College and Hospital, Barishal, Bangladesh
S. M. Rokonuzzaman Department of Clinical Oncology, Combined Military Hospital, Dhaka, Bangladesh
Meher Zabin Department of Radiotherapy, Dhaka Medical College Hospital, Dhaka, Bangladesh
Kamrun Nahar Tania Department of Radiation Oncology, National Institute of Cancer Research and Hospital, Dhaka, Bangladesh
Arunangshu Das Department of Oncology, Square Hospitals Ltd., Dhaka, Bangladesh

DOI:

https://doi.org/10.18203/2320-6012.ijrms20250962

Keywords:

Metastasis, Lung cancer, Osimertinib, Patient characteristics

Abstract

Background: Lung cancer is a major cause of mortality worldwide and metastasis plays a vital role in determining treatment and survival rate. Osimertinib showed significant success in the treatment of lung cancer, as evidenced by the literature, however, this outcome varies according to age, site of metastasis, etc. The objective of this study was to obtain demographic information on patients and assess the frequency of metastatic sites based on their age and sex.

Methods: This descriptive cross-sectional study included eighty metastatic lung cancer patients on osimertinib therapy attending a tertiary level health facility in Dhaka, Bangladesh. Data were obtained through reviewing their clinical reports.

Results: According to the findings, the patients' mean (±SD) age was 60.95 ±13.98 years. Patients who were between the ages of 55 and 75 had the highest rate of metastases. Under the age of 55, brain metastases (27%) were more common in both sexes (16.2%). While spinal metastasis was more frequent in female patients (8.1%), skin metastasis was more common in male patients (16.2%). Skin metastases were most frequently observed in patients aged 55 to 65 (10.8%), followed by those aged 25 to 45 (5.4%).

Conclusions: Mid-age male patients have been observed to have more cases of brain metastases and metastatic lung cancer. The findings are not conclusive due to the small sample size but suggest that the site of metastasis varied according to the patient's demographic characteristics. Further research on this topic is recommended to yield evidence for practitioners and policymakers.

Metrics

Metrics Loading ...

References

Noronha V, Budukh A, Chaturvedi P, Anne S, Punjabi A, Bhaskar M, et al. Uniqueness of lung cancer in Southeast Asia. The Lancet Regional Health - Southeast Asia. 2024;27:100430 DOI: https://doi.org/10.1016/j.lansea.2024.100430

Santarpia M, Karachaliou N, Rosell R. Beyond platinum treatment for NSCLC: what does the future hold? Expert Rev Anticancer Ther. 2017;17(4):293-5. DOI: https://doi.org/10.1080/14737140.2017.1288103

Barnes TA, O’Kane GM, Vincent MD, Leighl NB. Third-generation tyrosine kinase inhibitors targeting epidermal growth factor receptor mutations in non-small cell lung cancer. Front Oncol. 2017;7:113. DOI: https://doi.org/10.3389/fonc.2017.00113

Choo JR, Tan CS, Soo RA. Treatment of EGFR T790M-positive non-small cell lung cancer. Targ Oncol. 2018;13(2):141-56. DOI: https://doi.org/10.1007/s11523-018-0554-5

Tan CS, Kumarakulasinghe NB, Huang YQ, Ang YL, Choo JR, Goh BC, et al. Third generation EGFR TKIs: current data and future directions. Mol Cancer. 2018;17(1):29. DOI: https://doi.org/10.1186/s12943-018-0778-0

Scott LJ. Osimertinib as first-line therapy in advanced NSCLC: a profile of its use. Drug Ther Perspect. 2018;34(8):351-7. DOI: https://doi.org/10.1007/s40267-018-0536-9

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Medi. 2018;378(2):113-25.

Joobeur S, Migaou A, Fahem N, Mhamed SC, Rouatbi N. Survival and prognostic factors of non-small-cell lung cancer among young people in central Tunisia. Pan Afri Medi J. 2020;35:19. DOI: https://doi.org/10.11604/pamj.2020.35.19.21100

Abbasi S, Badheeb A. Prognostic factors in advanced non‐small‐cell lung cancer patients: patient characteristics and type of chemotherapy. Lung Cancer Internat. 2011;2011(1):152125. DOI: https://doi.org/10.4061/2011/152125

Ferguson MK, Wang J, Hoffman PC, Haraf DJ, Olak J, Masters GA, et al. Sex-associated differences in survival of patients undergoing resection for lung cancer. Anna Thora Surg. 2000;69(1):245-9. DOI: https://doi.org/10.1016/S0003-4975(99)01078-4

Radzikowska E, Głaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol: J Europ Soci Med Oncol. 2002;13(7):1087-93. DOI: https://doi.org/10.1093/annonc/mdf187

Islam MR, Hasan AK, Khatun N, Ridi IN, Rasheed MM, Islam SM, et al. Demographic differentials of lung cancer survival in Bangladeshi patients. Plos one. 2021;16(12):e0261238.

Shimizu H, Tominaga S, Nishimura M, Urata A. Comparison of clinico-epidemiological features of lung cancer patients with and without a history of smoking. Japan J Clin Oncol. 1984;14(4):595-600.

Mäkitaro R, Pääkko P, Huhti E, Bloigu R, Kinnula VL. Prospective population-based study on the survival of patients with lung cancer. Europ Respirat J. 2002;19(6):1087-92. DOI: https://doi.org/10.1183/09031936.02.00048302

Liao ML, Gao YT, Yang ZP. Prognostic factors in lung cancer based on Shanghai population. Chin J Tubercul Respir Dis. 1993;16(1):36-8.

Islam MR, Hasan AK, Khatun N, Ridi IN, Rasheed MM, Islam SM, Karim MN. Demographic differentials of lung cancer survival in Bangladeshi patients. Plos one. 2021;16(12):e0261238. DOI: https://doi.org/10.1371/journal.pone.0261238

Xie T, Qiu BM, Luo J, Diao YF, Hu LW, Liu XL, et al. Distant metastasis patterns among lung cancer subtypes and impact of primary tumor resection on survival in metastatic lung cancer using SEER database. Sci Rep. 2024;14(1):22445. DOI: https://doi.org/10.1038/s41598-024-73389-6

Park HK, Han J, Kwon GY, Yeo MK, Bae GE. Patterns of extrathoracic metastasis in lung cancer patients. Current Oncol. 2022;29(11):8794-801. DOI: https://doi.org/10.3390/curroncol29110691

Riihimäki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, et al. Metastatic sites and survival in lung cancer. Lung cancer. 2014;86(1):78-84. DOI: https://doi.org/10.1016/j.lungcan.2014.07.020

Sun T, Warrington NM, Rubin JB. Why does Jack, and not Jill, break his crown? Sex disparity in brain tumors. Biology of sex differences. 2012;3:1-0. DOI: https://doi.org/10.1186/2042-6410-3-3

Farach-Carson MC, Lin SH, Nalty T, Satcher RL. Sex differences and bone metastases of breast, lung, and prostate cancers: do bone homing cancers favor feminized bone marrow?. Front Oncol. 2017;7:163. DOI: https://doi.org/10.3389/fonc.2017.00163

Kazmi N, Márquez-Garbán DC, Aivazyan L, Hamilton N, Garon EB, Goodglick L, Pietras RJ. The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer. Lung Cancer Manag. 2012;1(4):259-72. DOI: https://doi.org/10.2217/lmt.12.44

Kerr A, II, Eliason JF, Wittliff JL. Steroid receptor and growth factor receptor expression in human nonsmall cell lung cancers using cells procured by laser-capture microdissection. Adv Exp Med Biol. 2008;617:377-84. DOI: https://doi.org/10.1007/978-0-387-69080-3_36

Zou J, Guo S, Xiong MT, Xu Y, Shao J, Tong Z, et al. Ageing as key factor for distant metastasis patterns and prognosis in patients with extensive-stage small cell lung cancer. J Canc. 2021;12(6):1575. DOI: https://doi.org/10.7150/jca.49681

Liu L, Bai H, Seery S, Li S, Wang C, Xue P, et al. Efficacy and safety of treatment modalities across EGFR selected/unselected populations with non-small cell lung cancer and brain metastases: a systematic review and Bayesian network meta-analysis. Lung Cancer. 2021;158:74-84. DOI: https://doi.org/10.1016/j.lungcan.2021.02.031

Robinson ND, Canavan ME, Zhan PL, Udelsman BV, Pathak R, Boffa DJ, et al. Treatment patterns and clinical outcomes in patients with egfr-mutated non–small-cell lung cancer after progression on osimertinib. Clinical Lung Cancer. 2025;26(1):9-17. DOI: https://doi.org/10.1016/j.cllc.2024.09.006

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. New Engl J Medi. 2018;378(2):113-25. DOI: https://doi.org/10.1056/NEJMoa1713137

Xie L, Nagpal S, Wakelee HA, Li G, Soltys SG, Neal JW. Osimertinib for EGFR‐mutant lung cancer with brain metastases: results from a single‐center retrospective study. The Oncol. 2019;24(6):836-43. DOI: https://doi.org/10.1634/theoncologist.2018-0264